Ceftaroline-induced eosinophilic pneumonia

Area of Science:

• Pulmonology
• Infectious Diseases
• Pharmacology

Background:

• Ceftaroline is a cephalosporin antibiotic effective against methicillin-resistant Staphylococcus aureus (MRSA).
• MRSA bacteremia can complicate postoperative spinal infections, requiring effective antibiotic therapy.
• Adverse drug reactions, including pulmonary manifestations, can occur with antibiotic use.

Observation:

• A patient treated with ceftaroline for MRSA bacteremia developed dyspnea and hypoxemia.
• Chest imaging revealed diffuse bilateral infiltrates.
• Peripheral blood eosinophilia and bronchoalveolar lavage fluid with eosinophilic predominance were noted.

Findings:

• The clinical presentation and laboratory findings were consistent with drug-induced eosinophilic pneumonia.
• Ceftaroline discontinuation and corticosteroid initiation led to complete resolution of symptoms and radiographic findings.
• This case highlights a potential adverse effect of ceftaroline therapy.

Implications:

• Ceftaroline should be considered as a potential cause of drug-induced eosinophilic pneumonia in patients presenting with compatible symptoms.
• Establishing diagnostic criteria for ceftaroline-induced eosinophilic pneumonia is crucial for timely diagnosis and management.
• Further investigation into the mechanisms of ceftaroline-induced pulmonary toxicity may inform future drug development and patient monitoring.